Annual Blood Tests Are an Acceptable Form of Surveillance to Supplement Colonoscopies for Colorectal Cancer

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2025 Feb 20

PMID 39976830

Authors

Rishabh Goyal

Carlene J Wilson

Ingrid H Flight

Charles Cock

Graeme P Young

Molla M Wassie

Sarah Cohen-Woods

Erin L Symonds

Maddison Dix

Affiliations

Soon will be listed here.

Abstract

Background: Individuals at increased risk of colorectal cancer (CRC) are recommended surveillance colonoscopies as a preventative measure, but timely provision of colonoscopies remains a significant hurdle. Biomarker testing has emerged as a potential strategy to mitigate excessive colonoscopy use by prioritizing procedures for those most at risk of CRC. However, the acceptability of supplementing surveillance colonoscopies with regular blood tests is unknown.

Aim: To evaluate patient acceptance of a hypothetical surveillance protocol providing annual blood tests between 5-yearly colonoscopies.

Methods: Eight hundred individuals enrolled in an Australian surveillance colonoscopy program were invited to complete a survey on surveillance preferences. Ordinal logistic regression analysis was performed to assess the influence of sociodemographic, clinical, and psychological variables on participants' comfort with the surveillance protocol.

Results: A total of 409 (51%) individuals participated, with 346 (51% male, mean age 63 years) providing complete outcome data. Most participants (n = 250/346, 72%) reported being comfortable with the surveillance protocol. Significantly higher levels of comfort were reported by individuals with greater confidence in their ability to undergo blood testing (OR 1.26, 95% CI 1.08-1.47, p = 0.003) and those having less frequent surveillance colonoscopies (OR 1.26, 95% CI 1.01-1.58, p = 0.043). Significant associations were not observed between other variables and comfort with the surveillance protocol (p > 0.05).

Conclusions: Annual blood testing between surveillance colonoscopies was highly accepted by individuals at increased risk of CRC. Offering new blood-based modalities to specific subpopulations, particularly individuals who are more comfortable with blood testing, or those having less frequent surveillance colonoscopies, could enhance overall acceptance.

References

Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag C, Laversanne M . Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023; 72(2):338-344. DOI: 10.1136/gutjnl-2022-327736. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Zauber A . The impact of screening on colorectal cancer mortality and incidence: has it really made a difference?. Dig Dis Sci. 2015; 60(3):681-91. PMC: 4412262. DOI: 10.1007/s10620-015-3600-5. View

Jung Y . Summary and comparison of recently updated post-polypectomy surveillance guidelines. Intest Res. 2023; 21(4):443-451. PMC: 10626009. DOI: 10.5217/ir.2023.00107. View

Kruse G, Khan S, Zaslavsky A, Ayanian J, Sequist T . Overuse of colonoscopy for colorectal cancer screening and surveillance. J Gen Intern Med. 2014; 30(3):277-83. PMC: 4351286. DOI: 10.1007/s11606-014-3015-6. View

Stock C, Holleczek B, Hoffmeister M, Stolz T, Stegmaier C, Brenner H . Adherence to physician recommendations for surveillance in opportunistic colorectal cancer screening: the necessity of organized surveillance. PLoS One. 2013; 8(12):e82676. PMC: 3855836. DOI: 10.1371/journal.pone.0082676. View

van Wifferen F, de Jonge L, Worthington J, Greuter M, Lew J, Nadeau C . Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study. J Med Screen. 2022; 29(2):72-83. PMC: 9087314. DOI: 10.1177/09691413211056777. View

Young G, Symonds E, Allison J, Cole S, Fraser C, Halloran S . Advances in Fecal Occult Blood Tests: the FIT revolution. Dig Dis Sci. 2014; 60(3):609-22. PMC: 4366567. DOI: 10.1007/s10620-014-3445-3. View

Wassie M, Young G, Cock C, Bampton P, Winter J, Simpson K . Faecal immunochemical test mitigates risk of delayed colonoscopy in people with elevated risk of colorectal neoplasia. J Gastroenterol Hepatol. 2022; 37(6):1067-1075. DOI: 10.1111/jgh.15823. View

10.

Greuter M, de Klerk C, Meijer G, Dekker E, Coupe V . Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis. Ann Intern Med. 2017; 167(8):544-554. DOI: 10.7326/M16-2891. View

11.

Wassie M, Dix M, Laven-Law G, Bulamu N, Cock C, Bampton P . Accuracy, Acceptability, and Application: Fecal Immunochemical Tests for Early Detection of Advanced Neoplasia in Colonoscopy-Based Surveillance. Dig Dis Sci. 2024; 69(7):2621-2630. PMC: 11258152. DOI: 10.1007/s10620-024-08466-x. View

12.

Klabunde C, Blom J, Bulliard J, Garcia M, Hagoel L, Mai V . Participation rates for organized colorectal cancer screening programmes: an international comparison. J Med Screen. 2015; 22(3):119-26. DOI: 10.1177/0969141315584694. View

13.

Symonds E, Simpson K, Coats M, Chaplin A, Saxty K, Sandford J . A nurse-led model at public academic hospitals maintains high adherence to colorectal cancer surveillance guidelines. Med J Aust. 2018; 208(11):492-496. DOI: 10.5694/mja17.00823. View

14.

Dix M, Wilson C, Flight I, Wassie M, Young G, Cock C . Patient attitudes towards changes in colorectal cancer surveillance: An application of the Health Belief Model. Eur J Cancer Care (Engl). 2022; 31(6):e13713. DOI: 10.1111/ecc.13713. View

15.

Rosenstock I, Strecher V, BECKER M . Social learning theory and the Health Belief Model. Health Educ Q. 1988; 15(2):175-83. DOI: 10.1177/109019818801500203. View

16.

Anderson L, Dedrick R . Development of the Trust in Physician scale: a measure to assess interpersonal trust in patient-physician relationships. Psychol Rep. 1990; 67(3 Pt 2):1091-100. DOI: 10.2466/pr0.1990.67.3f.1091. View

17.

Zajac I, Duncan A, Turnbull D, Wilson C, Flight I . Blood-based screening for bowel cancer may not resolve suboptimal screening participation in Australia. Aust N Z J Public Health. 2016; 40(4):337-41. DOI: 10.1111/1753-6405.12523. View

18.

Ali O, Gupta S, Brain K, Lifford K, Paranjothy S, Dolwani S . Acceptability of alternative technologies compared with faecal immunochemical test and/or colonoscopy in colorectal cancer screening: A systematic review. J Med Screen. 2022; 30(1):14-27. PMC: 9925898. DOI: 10.1177/09691413221109999. View

19.

Laven-Law G, Symonds E, Winter J, Chen G, Flight I, Hughes-Barton D . Comparing a fecal immunochemical test and circulating tumor DNA blood test for colorectal cancer screening adherence. J Gastroenterol Hepatol. 2024; 39(7):1267-1276. DOI: 10.1111/jgh.16531. View

20.

Osborne J, Flight I, Wilson C, Chen G, Ratcliffe J, Young G . The impact of sample type and procedural attributes on relative acceptability of different colorectal cancer screening regimens. Patient Prefer Adherence. 2018; 12:1825-1836. PMC: 6154741. DOI: 10.2147/PPA.S172143. View